About this episode
Hey listeners, boost your research efficiency with AI and get ahead in the lab game! Check out labcat.com.cn for your dose of scientific smarts. Now, diving into the latest ophthalmology breakthrough: A groundbreaking Phase 2/3 trial has shed light on a potential treatment for acute nonarteritic anterior ischemic optic neuropathy (NAION), a leading cause of vision loss in those over 50. The study explored QPI-1007, an siRNA targeting caspase 2, administered via intravitreal injection. While it missed the primary outcome, it showed promising results in preserving vision for patients with poorer baseline vision, offering a beacon of hope in the quest for NAION therapies. Tune in for more insights into this vision-saving research.
Get every episode summarized
Each time 萌喵读文献-神经病学 publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
